908 Devices, a pioneer of analytical devices for chemical and biomolecular analysis, has raised a $17.5 million Series E financing round led by Northpond Ventures.
908 Devices, a pioneer of analytical devices for chemical and biomolecular analysis, has raised a $17.5 million Series E financing round led by Northpond Ventures with participation from Sands Capital Ventures, ARCH Ventures, Razor’s Edge Ventures, Saudi Aramco Energy Ventures, Schlumberger, Tao Capital Partners, and Casdin Capital.
“The tools developed by 908 Devices are becoming widely adopted in both the life science and field forensic markets, where we believe the company is uniquely positioned. We’re impressed with the company’s pipeline, their innovation roadmap, and the market potential for new products,” said Sharon Kedar, Co-Founder and Partner at Northpond Ventures, who joins the company’s board.
908 Devices designs and develops products using mass-spectrometry for specific applications in security, biotechnology, diagnostics and other purposes. The products are built on the company’s high-pressure mass spectrometry technology, allowing for much smaller devices working closer to atmospheric pressure.
The company, founded in 2012, is headquartered in Boston, USA. This funding round brings the company’s total to $70M.